Gene Therapy Platform Developed by Neena Haider, PhD, Granted FDA Orphan Drug Designation February 27, 2019OCU400, a novel gene therapy platform developed by Neena Haider, PhD, Harvard Medical School Associate Professor of Ophthalmology and Associate Scientist at the Schepens Eye Research Institute of Mass. Eye and Ear, and licensed to biopharmaceutical company Ocugen, Inc., has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA).... Read more about Gene Therapy Platform Developed by Neena Haider, PhD, Granted FDA Orphan Drug Designation
Ocugen Expands Focus on Inherited Retinal Disorders by Licensing Novel Modifier Gene Therapy Platform December 20, 2017 Ocugen, Inc. has obtained an exclusive worldwide license to develop and commercialize future ophthalmology products based on groundbreaking technology developed by Neena Haider, PhD, Associate Professor of Ophthalmology.... Read more about Ocugen Expands Focus on Inherited Retinal Disorders by Licensing Novel Modifier Gene Therapy Platform
Harvard Ophthalmology faculty meet with members of Congress to advocate for vision research October 24, 2017 As part of the Alliance for Eye and Vision Research (AEVR) Emerging Vision Scientists Program, Neena Haider, PhD, and Hajirah Saeed, MD... Read more about Harvard Ophthalmology faculty meet with members of Congress to advocate for vision research